Skip to main content
. Author manuscript; available in PMC: 2024 Oct 1.
Published in final edited form as: Contemp Clin Trials. 2023 Sep 18;133:107334. doi: 10.1016/j.cct.2023.107334

Table 1.

Measure administration schedule

Measure Abbreviation Assessment Points Measure Type
Overall Anxiety Severity and Impairment Scale OASIS Screening Assessor administered
Mini Mental State Examination MMSE Screening Assessor administered
Structured Clinical Interview for DSM-5 SCID-5 Screening Assessor administered
Demographics N/A Baseline Self-report
Pain, Enjoyment, General Activity Scale PEG Baseline Self-report
Timeline Followback TLFB Baseline (past 30 days), Weekly (past 7 days), Post-treatment (past 30 days), 2-mo follow-up (past 30 days) Self-report
Urine Drug Screen UDS Baseline, Post-treatment, 2-mo follow-up Biological sample, collected over video call
Credibility and Expectancy Questionnaire CEQ Week 2 Self-report
Depression, Anxiety, and Stress Scale DASS-21 Weekly Self-report
Adverse Events N/A Weekly Self-report
Anxiety Sensitivity Index ASI-3 Biweekly Self-report
Pain Catastrophizing Scale PCS Biweekly Self-report
Treatment Satisfaction Questionnaire TSQ Post-treatment Self-report
Yale Adherence and Competence Scale YACS Following treatment completion Completed by rater